�ݺ�ߣshows by User: lipogemsequine

�ݺ�ߣshows by User: lipogemsequine / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: lipogemsequine / Wed, 29 May 2019 08:34:02 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: lipogemsequine Equestrian Life June 2019 /slideshow/equestrian-life-june-2019/148099917 26-27eqlifemay19-lipogemsfinal-190529083402
Ellie the Exmoor Feature on her treatment with Lead Lipogems Equine Veterinary Surgeon Dr Tim Watson from Waterlane Equine Vets ]]>
Ellie the Exmoor Feature on her treatment with Lead Lipogems Equine Veterinary Surgeon Dr Tim Watson from Waterlane Equine Vets ]]> Wed, 29 May 2019 08:34:02 GMT /slideshow/equestrian-life-june-2019/148099917 lipogemsequine@slideshare.net(lipogemsequine) Equestrian Life June 2019 lipogemsequine Ellie the Exmoor Feature on her treatment with Lead Lipogems Equine Veterinary Surgeon Dr Tim Watson from Waterlane Equine Vets <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/26-27eqlifemay19-lipogemsfinal-190529083402-thumbnail.jpg?width=120&height=120&fit=bounds" /> Ellie the Exmoor Feature on her treatment with Lead Lipogems Equine Veterinary Surgeon Dr Tim Watson from Waterlane Equine Vets

Equestrian Life June 2019 from Lipogems Equine & Lipogems Canine

]]> 329 2 https://cdn.slidesharecdn.com/ss_thumbnails/26-27eqlifemay19-lipogemsfinal-190529083402-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 A Selection of Lipogems Canine Case Studies v1. /slideshow/a-selection-of-lipogems-canine-case-studies-v1/119613895 aselectionoflipogemscaninecasestudiesv1-181016151016
A Selection of Lipogems Canine Case Studies v1. Pg 3. Introduction to cases Pg 4. Case 1. Gilda ~ GSD, F, 8Y, UAP, DJD Pg 8. Case 2. English Setter, M, 2Y, Old elbow fracture Pg 10. Case 3. Working collie, Bicipital tendon partial tear Pg 12. Case 4. Golden Retriever, Collateral ligaments, cruciate right stifle rupture Pg 14. Case 5. Pet Dog, Arthritic post cruciate tear Pg 16. Case 6. Torn medial meniscus Pg 17. Further links and contacts ]]>
A Selection of Lipogems Canine Case Studies v1. Pg 3. Introduction to cases Pg 4. Case 1. Gilda ~ GSD, F, 8Y, UAP, DJD Pg 8. Case 2. English Setter, M, 2Y, Old elbow fracture Pg 10. Case 3. Working collie, Bicipital tendon partial tear Pg 12. Case 4. Golden Retriever, Collateral ligaments, cruciate right stifle rupture Pg 14. Case 5. Pet Dog, Arthritic post cruciate tear Pg 16. Case 6. Torn medial meniscus Pg 17. Further links and contacts ]]> Tue, 16 Oct 2018 15:10:16 GMT /slideshow/a-selection-of-lipogems-canine-case-studies-v1/119613895 lipogemsequine@slideshare.net(lipogemsequine) A Selection of Lipogems Canine Case Studies v1. lipogemsequine A Selection of Lipogems Canine Case Studies v1. Pg 3. Introduction to cases Pg 4. Case 1. Gilda ~ GSD, F, 8Y, UAP, DJD Pg 8. Case 2. English Setter, M, 2Y, Old elbow fracture Pg 10. Case 3. Working collie, Bicipital tendon partial tear Pg 12. Case 4. Golden Retriever, Collateral ligaments, cruciate right stifle rupture Pg 14. Case 5. Pet Dog, Arthritic post cruciate tear Pg 16. Case 6. Torn medial meniscus Pg 17. Further links and contacts <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aselectionoflipogemscaninecasestudiesv1-181016151016-thumbnail.jpg?width=120&height=120&fit=bounds" /> A Selection of Lipogems Canine Case Studies v1. Pg 3. Introduction to cases Pg 4. Case 1. Gilda ~ GSD, F, 8Y, UAP, DJD Pg 8. Case 2. English Setter, M, 2Y, Old elbow fracture Pg 10. Case 3. Working collie, Bicipital tendon partial tear Pg 12. Case 4. Golden Retriever, Collateral ligaments, cruciate right stifle rupture Pg 14. Case 5. Pet Dog, Arthritic post cruciate tear Pg 16. Case 6. Torn medial meniscus Pg 17. Further links and contacts

A Selection of Lipogems Canine Case Studies v1. from Lipogems Equine & Lipogems Canine

]]> 335 7 https://cdn.slidesharecdn.com/ss_thumbnails/aselectionoflipogemscaninecasestudiesv1-181016151016-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes /slideshow/intraarticular-administration-of-autologous-microfragmented-adipose-tissue-in-dogs-with-spontaneous-osteoarthritis-safety-feasibility-and-clinical-outcomes/107283235 intra-1-180724105034
Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes OFFER ZEIRA,a SIMONE SCACCIA,a LETIZIA PETTINARI,a ERICA GHEZZI,a NIMROD ASIAG,a LAURA MARTINELLI,a DANIELE ZAHIRPOUR,a MARIA P. DUMAS,a MARTIN KONAR,a DAVIDE M. LUPI,a LAURENCE FIETTE,b LUISA PASCUCCI,c LEONARDO LEONARDI,c ALISTAIR CLIFF,d GIULIO ALESSANDRI,e AUGUSTO PESSINA,f DANIELE SPAZIANTE,g MARINA ARALLAa ABSTRACT Similar to the disease affecting humans, osteoarthritis (OA) is a painful musculoskeletal condition affecting 20% of the adult canine population. Several solutions have been proposed, but the results achieved to date are far from being satisfactory. New approaches, such as intra-articular delivery of cells (including mesenchymal stromal cells), have been proposed. Among the many sources, the adipose tissue is considered very promising. We evaluated the safety, feasibility, and efﬁcacy of a single intra-articular injection of autologous and micro-fragmented adipose tissue (MFAT) in 130 dogs with spontaneous OA. MFAT was obtained using a minimally invasive technique in a closed system and injected in the intra- and/or peri-articular space. Clinical outcomes were determined using orthopedic examination and owners’ scores for up to 6 months. In 78% of the dogs, improvement in the orthopedic score was registered 1 month after treatment and continued gradually up to 6 months when 88% of the dogs improved, 11% did not change, and 1% worsened compared with baseline. Considering the owners’ scores at 6 months, 92% of the dogs signiﬁcantly improved, 6% improved only slightly, and 2% worsened compared with baseline. No local or systemic major adverse effects were recorded. The results of this study suggest that MFAT injection in dogs with OA is safe, feasible, and beneﬁcial. The procedure is time sparing and cost-effective. Post injection cytological investigation, together with the clinical evidence, suggests a long-term pain control role of this treatment. The spontaneous OA dog model has a key role in developing successful treatments for translational medicine. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:1–10]]>
Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes OFFER ZEIRA,a SIMONE SCACCIA,a LETIZIA PETTINARI,a ERICA GHEZZI,a NIMROD ASIAG,a LAURA MARTINELLI,a DANIELE ZAHIRPOUR,a MARIA P. DUMAS,a MARTIN KONAR,a DAVIDE M. LUPI,a LAURENCE FIETTE,b LUISA PASCUCCI,c LEONARDO LEONARDI,c ALISTAIR CLIFF,d GIULIO ALESSANDRI,e AUGUSTO PESSINA,f DANIELE SPAZIANTE,g MARINA ARALLAa ABSTRACT Similar to the disease affecting humans, osteoarthritis (OA) is a painful musculoskeletal condition affecting 20% of the adult canine population. Several solutions have been proposed, but the results achieved to date are far from being satisfactory. New approaches, such as intra-articular delivery of cells (including mesenchymal stromal cells), have been proposed. Among the many sources, the adipose tissue is considered very promising. We evaluated the safety, feasibility, and efﬁcacy of a single intra-articular injection of autologous and micro-fragmented adipose tissue (MFAT) in 130 dogs with spontaneous OA. MFAT was obtained using a minimally invasive technique in a closed system and injected in the intra- and/or peri-articular space. Clinical outcomes were determined using orthopedic examination and owners’ scores for up to 6 months. In 78% of the dogs, improvement in the orthopedic score was registered 1 month after treatment and continued gradually up to 6 months when 88% of the dogs improved, 11% did not change, and 1% worsened compared with baseline. Considering the owners’ scores at 6 months, 92% of the dogs signiﬁcantly improved, 6% improved only slightly, and 2% worsened compared with baseline. No local or systemic major adverse effects were recorded. The results of this study suggest that MFAT injection in dogs with OA is safe, feasible, and beneﬁcial. The procedure is time sparing and cost-effective. Post injection cytological investigation, together with the clinical evidence, suggests a long-term pain control role of this treatment. The spontaneous OA dog model has a key role in developing successful treatments for translational medicine. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:1–10]]> Tue, 24 Jul 2018 10:50:34 GMT /slideshow/intraarticular-administration-of-autologous-microfragmented-adipose-tissue-in-dogs-with-spontaneous-osteoarthritis-safety-feasibility-and-clinical-outcomes/107283235 lipogemsequine@slideshare.net(lipogemsequine) Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes lipogemsequine Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes OFFER ZEIRA,a SIMONE SCACCIA,a LETIZIA PETTINARI,a ERICA GHEZZI,a NIMROD ASIAG,a LAURA MARTINELLI,a DANIELE ZAHIRPOUR,a MARIA P. DUMAS,a MARTIN KONAR,a DAVIDE M. LUPI,a LAURENCE FIETTE,b LUISA PASCUCCI,c LEONARDO LEONARDI,c ALISTAIR CLIFF,d GIULIO ALESSANDRI,e AUGUSTO PESSINA,f DANIELE SPAZIANTE,g MARINA ARALLAa ABSTRACT Similar to the disease affecting humans, osteoarthritis (OA) is a painful musculoskeletal condition affecting 20% of the adult canine population. Several solutions have been proposed, but the results achieved to date are far from being satisfactory. New approaches, such as intra-articular delivery of cells (including mesenchymal stromal cells), have been proposed. Among the many sources, the adipose tissue is considered very promising. We evaluated the safety, feasibility, and efﬁcacy of a single intra-articular injection of autologous and micro-fragmented adipose tissue (MFAT) in 130 dogs with spontaneous OA. MFAT was obtained using a minimally invasive technique in a closed system and injected in the intra- and/or peri-articular space. Clinical outcomes were determined using orthopedic examination and owners’ scores for up to 6 months. In 78% of the dogs, improvement in the orthopedic score was registered 1 month after treatment and continued gradually up to 6 months when 88% of the dogs improved, 11% did not change, and 1% worsened compared with baseline. Considering the owners’ scores at 6 months, 92% of the dogs signiﬁcantly improved, 6% improved only slightly, and 2% worsened compared with baseline. No local or systemic major adverse effects were recorded. The results of this study suggest that MFAT injection in dogs with OA is safe, feasible, and beneﬁcial. The procedure is time sparing and cost-effective. Post injection cytological investigation, together with the clinical evidence, suggests a long-term pain control role of this treatment. The spontaneous OA dog model has a key role in developing successful treatments for translational medicine. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:1–10 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/intra-1-180724105034-thumbnail.jpg?width=120&height=120&fit=bounds" /> Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes OFFER ZEIRA,a SIMONE SCACCIA,a LETIZIA PETTINARI,a ERICA GHEZZI,a NIMROD ASIAG,a LAURA MARTINELLI,a DANIELE ZAHIRPOUR,a MARIA P. DUMAS,a MARTIN KONAR,a DAVIDE M. LUPI,a LAURENCE FIETTE,b LUISA PASCUCCI,c LEONARDO LEONARDI,c ALISTAIR CLIFF,d GIULIO ALESSANDRI,e AUGUSTO PESSINA,f DANIELE SPAZIANTE,g MARINA ARALLAa ABSTRACT Similar to the disease affecting humans, osteoarthritis (OA) is a painful musculoskeletal condition affecting 20% of the adult canine population. Several solutions have been proposed, but the results achieved to date are far from being satisfactory. New approaches, such as intra-articular delivery of cells (including mesenchymal stromal cells), have been proposed. Among the many sources, the adipose tissue is considered very promising. We evaluated the safety, feasibility, and efﬁcacy of a single intra-articular injection of autologous and micro-fragmented adipose tissue (MFAT) in 130 dogs with spontaneous OA. MFAT was obtained using a minimally invasive technique in a closed system and injected in the intra- and/or peri-articular space. Clinical outcomes were determined using orthopedic examination and owners’ scores for up to 6 months. In 78% of the dogs, improvement in the orthopedic score was registered 1 month after treatment and continued gradually up to 6 months when 88% of the dogs improved, 11% did not change, and 1% worsened compared with baseline. Considering the owners’ scores at 6 months, 92% of the dogs signiﬁcantly improved, 6% improved only slightly, and 2% worsened compared with baseline. No local or systemic major adverse effects were recorded. The results of this study suggest that MFAT injection in dogs with OA is safe, feasible, and beneﬁcial. The procedure is time sparing and cost-effective. Post injection cytological investigation, together with the clinical evidence, suggests a long-term pain control role of this treatment. The spontaneous OA dog model has a key role in developing successful treatments for translational medicine. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:1–10

Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes from Lipogems Equine & Lipogems Canine

]]> 529 6 https://cdn.slidesharecdn.com/ss_thumbnails/intra-1-180724105034-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast bitoech uk privacy and data protection policy /lipogemsequine/lipocast-bitoech-uk-privacy-and-data-protection-policy lipocastbitoechukprivacyanddataprotectionpolicy-180525112234
Lipocast bitoech uk privacy and data protection policy]]>
Lipocast bitoech uk privacy and data protection policy]]> Fri, 25 May 2018 11:22:34 GMT /lipogemsequine/lipocast-bitoech-uk-privacy-and-data-protection-policy lipogemsequine@slideshare.net(lipogemsequine) Lipocast bitoech uk privacy and data protection policy lipogemsequine Lipocast bitoech uk privacy and data protection policy <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbitoechukprivacyanddataprotectionpolicy-180525112234-thumbnail.jpg?width=120&height=120&fit=bounds" /> Lipocast bitoech uk privacy and data protection policy

Lipocast bitoech uk privacy and data protection policy from Lipogems Equine & Lipogems Canine

]]> 205 3 https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbitoechukprivacyanddataprotectionpolicy-180525112234-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipogems regenerative medicine seminar by lipocast biotech uk itinerary for shared files /slideshow/lipogems-regenerative-medicine-seminar-by-lipocast-biotech-uk-itinerary-for-shared-files/97156016 lipogemsregenerativemedicineseminarbylipocastbiotechukitineraryforsharedfiles-180515120206
The itinerary and keynote speaker list for the May 2018 Lipogems Regenerative Medicine Seminar]]>
The itinerary and keynote speaker list for the May 2018 Lipogems Regenerative Medicine Seminar]]> Tue, 15 May 2018 12:02:06 GMT /slideshow/lipogems-regenerative-medicine-seminar-by-lipocast-biotech-uk-itinerary-for-shared-files/97156016 lipogemsequine@slideshare.net(lipogemsequine) Lipogems regenerative medicine seminar by lipocast biotech uk itinerary for shared files lipogemsequine The itinerary and keynote speaker list for the May 2018 Lipogems Regenerative Medicine Seminar <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipogemsregenerativemedicineseminarbylipocastbiotechukitineraryforsharedfiles-180515120206-thumbnail.jpg?width=120&height=120&fit=bounds" /> The itinerary and keynote speaker list for the May 2018 Lipogems Regenerative Medicine Seminar

Lipogems regenerative medicine seminar by lipocast biotech uk itinerary for shared files from Lipogems Equine & Lipogems Canine

]]> 67 1 https://cdn.slidesharecdn.com/ss_thumbnails/lipogemsregenerativemedicineseminarbylipocastbiotechukitineraryforsharedfiles-180515120206-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Vet Times February Issue 2018 /slideshow/vet-times-february-issue-2018/92060916 vte4-180327142433
THE company behind an innovative product “that is revolutionising how vets are able to treat tendon and ligament injuries” is planning a seminar in May to showcase treatment options, techniques, the science and clinical data. Lipocast Biotech UK brought Lipogems Equine and Canine to the UK market and said the treatment had “grown exponentially” in 2017 due to success accredited veterinary surgeons are seeing in equine and canine patients. Use in international veterinary schools is adding to positive testaments of the treatment’s capability, the firm said. A database of studies is being compiled for both equine and canine patients, with Tim Watson, of Waterlane Equine Vets, Gloucestershire, leading collection of the equine data. Lipogems offers, says Lipocast, a rapid and cost-effective means of harvesting mesenchymal stromal cells (MSCs), helping vets treat tendon and ligament injuries and manage degenerative joint diseases. Lipogems harnesses, says Lipocast Biotech, the potential of pericyte cells that surround capillaries. Following tissue injury, pericytes detach from the capillaries and gradually convert into activated MSCs and begin the process of orchestrating tissue repair. The Lipogems technique delivers MSCs from pericytes in adipose tissue that are collected by liposuction, flushed and processed using gentle mechanical disruption. These MSCs understand the nature of the injury into which they are injected and then stimulate and coordinate numerous biological processes for effective healing. For equine veterinary surgeons, the procedure can be performed stable-side in 40 minutes, with no additional culture or laboratory time is required. Lipocast Biotech UK has now announced the inaugural Lipogems Regenerative Medicine Seminar will be held on 16 May in Cirencester, Gloucestershire. The seminar, which offers five CPD hours, is free of charge, and leading vets will give lectures about the future of regenerative medicine and the science behind the technology, with case-based evidence and procedure demonstrations presented. Dr Watson said: “Lipogems is an easy technique that can be performed at the patient's side and enables prompt treatment for a wide range of common orthopaedic conditions affecting horses and ponies. The results are superior to other regenerative therapies currently used.” For more details about the seminar, email lucy_wilson@lipogemsequine.com ]]>
THE company behind an innovative product “that is revolutionising how vets are able to treat tendon and ligament injuries” is planning a seminar in May to showcase treatment options, techniques, the science and clinical data. Lipocast Biotech UK brought Lipogems Equine and Canine to the UK market and said the treatment had “grown exponentially” in 2017 due to success accredited veterinary surgeons are seeing in equine and canine patients. Use in international veterinary schools is adding to positive testaments of the treatment’s capability, the firm said. A database of studies is being compiled for both equine and canine patients, with Tim Watson, of Waterlane Equine Vets, Gloucestershire, leading collection of the equine data. Lipogems offers, says Lipocast, a rapid and cost-effective means of harvesting mesenchymal stromal cells (MSCs), helping vets treat tendon and ligament injuries and manage degenerative joint diseases. Lipogems harnesses, says Lipocast Biotech, the potential of pericyte cells that surround capillaries. Following tissue injury, pericytes detach from the capillaries and gradually convert into activated MSCs and begin the process of orchestrating tissue repair. The Lipogems technique delivers MSCs from pericytes in adipose tissue that are collected by liposuction, flushed and processed using gentle mechanical disruption. These MSCs understand the nature of the injury into which they are injected and then stimulate and coordinate numerous biological processes for effective healing. For equine veterinary surgeons, the procedure can be performed stable-side in 40 minutes, with no additional culture or laboratory time is required. Lipocast Biotech UK has now announced the inaugural Lipogems Regenerative Medicine Seminar will be held on 16 May in Cirencester, Gloucestershire. The seminar, which offers five CPD hours, is free of charge, and leading vets will give lectures about the future of regenerative medicine and the science behind the technology, with case-based evidence and procedure demonstrations presented. Dr Watson said: “Lipogems is an easy technique that can be performed at the patient's side and enables prompt treatment for a wide range of common orthopaedic conditions affecting horses and ponies. The results are superior to other regenerative therapies currently used.” For more details about the seminar, email lucy_wilson@lipogemsequine.com ]]> Tue, 27 Mar 2018 14:24:32 GMT /slideshow/vet-times-february-issue-2018/92060916 lipogemsequine@slideshare.net(lipogemsequine) Vet Times February Issue 2018 lipogemsequine THE company behind an innovative product “that is revolutionising how vets are able to treat tendon and ligament injuries” is planning a seminar in May to showcase treatment options, techniques, the science and clinical data. Lipocast Biotech UK brought Lipogems Equine and Canine to the UK market and said the treatment had “grown exponentially” in 2017 due to success accredited veterinary surgeons are seeing in equine and canine patients. Use in international veterinary schools is adding to positive testaments of the treatment’s capability, the firm said. A database of studies is being compiled for both equine and canine patients, with Tim Watson, of Waterlane Equine Vets, Gloucestershire, leading collection of the equine data. Lipogems offers, says Lipocast, a rapid and cost-effective means of harvesting mesenchymal stromal cells (MSCs), helping vets treat tendon and ligament injuries and manage degenerative joint diseases. Lipogems harnesses, says Lipocast Biotech, the potential of pericyte cells that surround capillaries. Following tissue injury, pericytes detach from the capillaries and gradually convert into activated MSCs and begin the process of orchestrating tissue repair. The Lipogems technique delivers MSCs from pericytes in adipose tissue that are collected by liposuction, flushed and processed using gentle mechanical disruption. These MSCs understand the nature of the injury into which they are injected and then stimulate and coordinate numerous biological processes for effective healing. For equine veterinary surgeons, the procedure can be performed stable-side in 40 minutes, with no additional culture or laboratory time is required. Lipocast Biotech UK has now announced the inaugural Lipogems Regenerative Medicine Seminar will be held on 16 May in Cirencester, Gloucestershire. The seminar, which offers five CPD hours, is free of charge, and leading vets will give lectures about the future of regenerative medicine and the science behind the technology, with case-based evidence and procedure demonstrations presented. Dr Watson said: “Lipogems is an easy technique that can be performed at the patient's side and enables prompt treatment for a wide range of common orthopaedic conditions affecting horses and ponies. The results are superior to other regenerative therapies currently used.” For more details about the seminar, email lucy_wilson@lipogemsequine.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/vte4-180327142433-thumbnail.jpg?width=120&height=120&fit=bounds" /> THE company behind an innovative product “that is revolutionising how vets are able to treat tendon and ligament injuries” is planning a seminar in May to showcase treatment options, techniques, the science and clinical data. Lipocast Biotech UK brought Lipogems Equine and Canine to the UK market and said the treatment had “grown exponentially” in 2017 due to success accredited veterinary surgeons are seeing in equine and canine patients. Use in international veterinary schools is adding to positive testaments of the treatment’s capability, the firm said. A database of studies is being compiled for both equine and canine patients, with Tim Watson, of Waterlane Equine Vets, Gloucestershire, leading collection of the equine data. Lipogems offers, says Lipocast, a rapid and cost-effective means of harvesting mesenchymal stromal cells (MSCs), helping vets treat tendon and ligament injuries and manage degenerative joint diseases. Lipogems harnesses, says Lipocast Biotech, the potential of pericyte cells that surround capillaries. Following tissue injury, pericytes detach from the capillaries and gradually convert into activated MSCs and begin the process of orchestrating tissue repair. The Lipogems technique delivers MSCs from pericytes in adipose tissue that are collected by liposuction, flushed and processed using gentle mechanical disruption. These MSCs understand the nature of the injury into which they are injected and then stimulate and coordinate numerous biological processes for effective healing. For equine veterinary surgeons, the procedure can be performed stable-side in 40 minutes, with no additional culture or laboratory time is required. Lipocast Biotech UK has now announced the inaugural Lipogems Regenerative Medicine Seminar will be held on 16 May in Cirencester, Gloucestershire. The seminar, which offers five CPD hours, is free of charge, and leading vets will give lectures about the future of regenerative medicine and the science behind the technology, with case-based evidence and procedure demonstrations presented. Dr Watson said: “Lipogems is an easy technique that can be performed at the patient's side and enables prompt treatment for a wide range of common orthopaedic conditions affecting horses and ponies. The results are superior to other regenerative therapies currently used.” For more details about the seminar, email lucy_wilson@lipogemsequine.com

Vet Times February Issue 2018 from Lipogems Equine & Lipogems Canine

]]> 140 6 https://cdn.slidesharecdn.com/ss_thumbnails/vte4-180327142433-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipogems Equine Featured in Polo Times February 2018 Issue /slideshow/lipogems-equine-featured-in-polo-times-february-2018-issue/87044156 lipogemsptfeb18002-180201140144
Check It Out Lipogems demonstrates how technology translated from humans for horses is paving the way for stopping career ending injuries in their tracks with a simple and effective yard-side procedure. Progress for polo pony injuries continues with Lipogems Equine]]>
Check It Out Lipogems demonstrates how technology translated from humans for horses is paving the way for stopping career ending injuries in their tracks with a simple and effective yard-side procedure. Progress for polo pony injuries continues with Lipogems Equine]]> Thu, 01 Feb 2018 14:01:44 GMT /slideshow/lipogems-equine-featured-in-polo-times-february-2018-issue/87044156 lipogemsequine@slideshare.net(lipogemsequine) Lipogems Equine Featured in Polo Times February 2018 Issue lipogemsequine Check It Out Lipogems demonstrates how technology translated from humans for horses is paving the way for stopping career ending injuries in their tracks with a simple and effective yard-side procedure. Progress for polo pony injuries continues with Lipogems Equine <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipogemsptfeb18002-180201140144-thumbnail.jpg?width=120&height=120&fit=bounds" /> Check It Out Lipogems demonstrates how technology translated from humans for horses is paving the way for stopping career ending injuries in their tracks with a simple and effective yard-side procedure. Progress for polo pony injuries continues with Lipogems Equine

Lipogems Equine Featured in Polo Times February 2018 Issue from Lipogems Equine & Lipogems Canine

]]> 245 6 https://cdn.slidesharecdn.com/ss_thumbnails/lipogemsptfeb18002-180201140144-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With Further Reading Links /slideshow/lipocast-biotech-uk-lipogems-equine-and-canine-presentation-2017-v12-with-further-reading-links/81151301 lipocastbiotechuklipogemsequineandcaninepresentation2017v-171024142252
This is a short presentation about the translation of Lipogems concept and technology for veterinary use in equine and canine application. This presentation also includes a series of download links to published papers, abstracts and study models from the human application. ]]>
This is a short presentation about the translation of Lipogems concept and technology for veterinary use in equine and canine application. This presentation also includes a series of download links to published papers, abstracts and study models from the human application. ]]> Tue, 24 Oct 2017 14:22:51 GMT /slideshow/lipocast-biotech-uk-lipogems-equine-and-canine-presentation-2017-v12-with-further-reading-links/81151301 lipogemsequine@slideshare.net(lipogemsequine) Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With Further Reading Links lipogemsequine This is a short presentation about the translation of Lipogems concept and technology for veterinary use in equine and canine application. This presentation also includes a series of download links to published papers, abstracts and study models from the human application. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineandcaninepresentation2017v-171024142252-thumbnail.jpg?width=120&height=120&fit=bounds" /> This is a short presentation about the translation of Lipogems concept and technology for veterinary use in equine and canine application. This presentation also includes a series of download links to published papers, abstracts and study models from the human application.

Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With Further Reading Links from Lipogems Equine & Lipogems Canine

]]> 327 3 https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineandcaninepresentation2017v-171024142252-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1 /slideshow/lipocast-biotech-uk-lipogems-canine-standard-operating-procedure-v1/80903151 lipogemscaninesopv1-171017152240
This file is a step by step guide of how to conduct a Lipogems Canine procedure with a list of disposables required and do's and don'ts as well as aftercare details.]]>
This file is a step by step guide of how to conduct a Lipogems Canine procedure with a list of disposables required and do's and don'ts as well as aftercare details.]]> Tue, 17 Oct 2017 15:22:40 GMT /slideshow/lipocast-biotech-uk-lipogems-canine-standard-operating-procedure-v1/80903151 lipogemsequine@slideshare.net(lipogemsequine) Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1 lipogemsequine This file is a step by step guide of how to conduct a Lipogems Canine procedure with a list of disposables required and do's and don'ts as well as aftercare details. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipogemscaninesopv1-171017152240-thumbnail.jpg?width=120&height=120&fit=bounds" /> This file is a step by step guide of how to conduct a Lipogems Canine procedure with a list of disposables required and do's and don'ts as well as aftercare details.

Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1 from Lipogems Equine & Lipogems Canine

]]> 136 2 https://cdn.slidesharecdn.com/ss_thumbnails/lipogemscaninesopv1-171017152240-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - without videos /slideshow/lipocast-biotech-uk-lipogems-equine-standard-operating-procedure-007-without-videos/80903055 lipocastbiotechuk-lipogemssop007-withoutvideos-171017152019
A step by step guide for the use of Lipogems Equine kits with a list of disposables required and do's and don'ts.]]>
A step by step guide for the use of Lipogems Equine kits with a list of disposables required and do's and don'ts.]]> Tue, 17 Oct 2017 15:20:19 GMT /slideshow/lipocast-biotech-uk-lipogems-equine-standard-operating-procedure-007-without-videos/80903055 lipogemsequine@slideshare.net(lipogemsequine) Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - without videos lipogemsequine A step by step guide for the use of Lipogems Equine kits with a list of disposables required and do's and don'ts. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuk-lipogemssop007-withoutvideos-171017152019-thumbnail.jpg?width=120&height=120&fit=bounds" /> A step by step guide for the use of Lipogems Equine kits with a list of disposables required and do's and don'ts.

Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - without videos from Lipogems Equine & Lipogems Canine

]]> 206 3 https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuk-lipogemssop007-withoutvideos-171017152019-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteoglycan Synthesis in Patients with Knee Osteoarthritis /slideshow/the-effect-of-intraarticular-injection-of-autologous-microfragmented-fat-tissue-on-proteoglycan-synthesis-in-patients-with-knee-osteoarthritis/80898771 genes-08-00270-171017133006
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteogly can Synthesis in Patients with Knee Osteoarthritis Damir Hudetz 1,2,3,*, Igor Borić 1,4,5, Eduard Rod 1, Željko Jeleč 1, Andrej Radić 1, Trpimir Vrdoljak 1,2, Andrea Skelin 1,6, Gordan Lauc 6,7, A prospective, non-randomized, interventional, single-center, open-label clinical trial was conducted from January 2016 to April 2017 Results The results of our study indicate that the use of autologous and micro-fragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results.]]>
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteogly can Synthesis in Patients with Knee Osteoarthritis Damir Hudetz 1,2,3,*, Igor Borić 1,4,5, Eduard Rod 1, Željko Jeleč 1, Andrej Radić 1, Trpimir Vrdoljak 1,2, Andrea Skelin 1,6, Gordan Lauc 6,7, A prospective, non-randomized, interventional, single-center, open-label clinical trial was conducted from January 2016 to April 2017 Results The results of our study indicate that the use of autologous and micro-fragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results.]]> Tue, 17 Oct 2017 13:30:06 GMT /slideshow/the-effect-of-intraarticular-injection-of-autologous-microfragmented-fat-tissue-on-proteoglycan-synthesis-in-patients-with-knee-osteoarthritis/80898771 lipogemsequine@slideshare.net(lipogemsequine) The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteoglycan Synthesis in Patients with Knee Osteoarthritis lipogemsequine The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteogly can Synthesis in Patients with Knee Osteoarthritis Damir Hudetz 1,2,3,*, Igor Borić 1,4,5, Eduard Rod 1, Željko Jeleč 1, Andrej Radić 1, Trpimir Vrdoljak 1,2, Andrea Skelin 1,6, Gordan Lauc 6,7, A prospective, non-randomized, interventional, single-center, open-label clinical trial was conducted from January 2016 to April 2017 Results The results of our study indicate that the use of autologous and micro-fragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/genes-08-00270-171017133006-thumbnail.jpg?width=120&height=120&fit=bounds" /> The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteogly can Synthesis in Patients with Knee Osteoarthritis Damir Hudetz 1,2,3,*, Igor Borić 1,4,5, Eduard Rod 1, Željko Jeleč 1, Andrej Radić 1, Trpimir Vrdoljak 1,2, Andrea Skelin 1,6, Gordan Lauc 6,7, A prospective, non-randomized, interventional, single-center, open-label clinical trial was conducted from January 2016 to April 2017 Results The results of our study indicate that the use of autologous and micro-fragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results.

The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteoglycan Synthesis in Patients with Knee Osteoarthritis from Lipogems Equine & Lipogems Canine

]]> 422 6 https://cdn.slidesharecdn.com/ss_thumbnails/genes-08-00270-171017133006-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Minimal Criteria for Defining MSC's. The ISCT Position Statement /slideshow/minimal-criteria-for-defining-mscs-the-isct-position-statement/80860811 minimal-criteria-for-defining-msc-171016143826
Minimal criteria for deﬁning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement M Dominici1, K Le Blanc2, I Mueller3, I Slaper-Cortenbach4, FC Marini5, DS Krause6, RJ Deans7, A Keating8, DJ Prockop9 and EM Horwitz10]]>
Minimal criteria for deﬁning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement M Dominici1, K Le Blanc2, I Mueller3, I Slaper-Cortenbach4, FC Marini5, DS Krause6, RJ Deans7, A Keating8, DJ Prockop9 and EM Horwitz10]]> Mon, 16 Oct 2017 14:38:26 GMT /slideshow/minimal-criteria-for-defining-mscs-the-isct-position-statement/80860811 lipogemsequine@slideshare.net(lipogemsequine) Minimal Criteria for Defining MSC's. The ISCT Position Statement lipogemsequine Minimal criteria for deﬁning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement M Dominici1, K Le Blanc2, I Mueller3, I Slaper-Cortenbach4, FC Marini5, DS Krause6, RJ Deans7, A Keating8, DJ Prockop9 and EM Horwitz10 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/minimal-criteria-for-defining-msc-171016143826-thumbnail.jpg?width=120&height=120&fit=bounds" /> Minimal criteria for deﬁning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement M Dominici1, K Le Blanc2, I Mueller3, I Slaper-Cortenbach4, FC Marini5, DS Krause6, RJ Deans7, A Keating8, DJ Prockop9 and EM Horwitz10

Minimal Criteria for Defining MSC's. The ISCT Position Statement from Lipogems Equine & Lipogems Canine

]]> 220 9 https://cdn.slidesharecdn.com/ss_thumbnails/minimal-criteria-for-defining-msc-171016143826-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* /slideshow/mammalian-msc-from-selected-species-features-and-applications-christiane-uder-sandra-bruckner-sandra-winkler-hansmichael-tautenhahn-bruno-christ/80860626 56a2b07d6d570e3f0efab33a0af9a23b1fc4058002ef5add943d7e8684b57b97-171016143430
Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD1051, CD731, CD901, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications.]]>
Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD1051, CD731, CD901, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications.]]> Mon, 16 Oct 2017 14:34:30 GMT /slideshow/mammalian-msc-from-selected-species-features-and-applications-christiane-uder-sandra-bruckner-sandra-winkler-hansmichael-tautenhahn-bruno-christ/80860626 lipogemsequine@slideshare.net(lipogemsequine) Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* lipogemsequine Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD1051, CD731, CD901, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/56a2b07d6d570e3f0efab33a0af9a23b1fc4058002ef5add943d7e8684b57b97-171016143430-thumbnail.jpg?width=120&height=120&fit=bounds" /> Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD1051, CD731, CD901, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications.

Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* from Lipogems Equine & Lipogems Canine

]]> 229 8 https://cdn.slidesharecdn.com/ss_thumbnails/56a2b07d6d570e3f0efab33a0af9a23b1fc4058002ef5add943d7e8684b57b97-171016143430-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development /lipogemsequine/adipose-tissue-and-mesenchymal-stem-cells-state-of-the-art-and-lipogems-technology-development tremoladaetal-2016-currentstemcellreports-2-171016142602
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development Carlo Tremolada1 & Valeria Colombo1 & Carlo Ventura2 Abstract Inthepastfewyears,interestinadiposetissueasan ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered Bmini-drugstores.^ MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinicalresults.Moreover, these techniquesare hampered by complex regulatory issues. Therefore, an innovative technique (Lipogems®; Lipogems International SpA, Milan, Italy) was developed to obtain microfragmented adipose tissue with an intact stromal vascular niche and MSCs with a high regenerative capacity. The Lipogems® technology, patented in 2010 and clinically available since 2013, is an easyto-use system designed to harvest, process, and inject refined fat tissue and is characterized by optimal handling ability and a great regenerative potential based on adipose-derived MSCs. In this novel technology, the adipose tissue is washed, emulsified, and rinsed and adipose cluster dimensions gradually are reduced to about 0.3 to 0.8 mm. In the resulting Lipogems® product, pericytes are retained within an intact stromal vascular niche and are ready to interact with the recipient tissue after transplantation, thereby becoming MSCs and starting the regenerative process. Lipogems® has been used in more than 7000 patients worldwide in aesthetic medicineandsurgery,aswellasinorthopedicandgeneralsurgery, with remarkable and promising results and seemingly no drawbacks. Now, several clinical trials are under way to supporttheinitialencouragingoutcomes.Lipogems®technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes.]]>
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development Carlo Tremolada1 & Valeria Colombo1 & Carlo Ventura2 Abstract Inthepastfewyears,interestinadiposetissueasan ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered Bmini-drugstores.^ MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinicalresults.Moreover, these techniquesare hampered by complex regulatory issues. Therefore, an innovative technique (Lipogems®; Lipogems International SpA, Milan, Italy) was developed to obtain microfragmented adipose tissue with an intact stromal vascular niche and MSCs with a high regenerative capacity. The Lipogems® technology, patented in 2010 and clinically available since 2013, is an easyto-use system designed to harvest, process, and inject refined fat tissue and is characterized by optimal handling ability and a great regenerative potential based on adipose-derived MSCs. In this novel technology, the adipose tissue is washed, emulsified, and rinsed and adipose cluster dimensions gradually are reduced to about 0.3 to 0.8 mm. In the resulting Lipogems® product, pericytes are retained within an intact stromal vascular niche and are ready to interact with the recipient tissue after transplantation, thereby becoming MSCs and starting the regenerative process. Lipogems® has been used in more than 7000 patients worldwide in aesthetic medicineandsurgery,aswellasinorthopedicandgeneralsurgery, with remarkable and promising results and seemingly no drawbacks. Now, several clinical trials are under way to supporttheinitialencouragingoutcomes.Lipogems®technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes.]]> Mon, 16 Oct 2017 14:26:02 GMT /lipogemsequine/adipose-tissue-and-mesenchymal-stem-cells-state-of-the-art-and-lipogems-technology-development lipogemsequine@slideshare.net(lipogemsequine) Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development lipogemsequine Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development Carlo Tremolada1 & Valeria Colombo1 & Carlo Ventura2 Abstract Inthepastfewyears,interestinadiposetissueasan ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered Bmini-drugstores.^ MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinicalresults.Moreover, these techniquesare hampered by complex regulatory issues. Therefore, an innovative technique (Lipogems®; Lipogems International SpA, Milan, Italy) was developed to obtain microfragmented adipose tissue with an intact stromal vascular niche and MSCs with a high regenerative capacity. The Lipogems® technology, patented in 2010 and clinically available since 2013, is an easyto-use system designed to harvest, process, and inject refined fat tissue and is characterized by optimal handling ability and a great regenerative potential based on adipose-derived MSCs. In this novel technology, the adipose tissue is washed, emulsified, and rinsed and adipose cluster dimensions gradually are reduced to about 0.3 to 0.8 mm. In the resulting Lipogems® product, pericytes are retained within an intact stromal vascular niche and are ready to interact with the recipient tissue after transplantation, thereby becoming MSCs and starting the regenerative process. Lipogems® has been used in more than 7000 patients worldwide in aesthetic medicineandsurgery,aswellasinorthopedicandgeneralsurgery, with remarkable and promising results and seemingly no drawbacks. Now, several clinical trials are under way to supporttheinitialencouragingoutcomes.Lipogems®technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/tremoladaetal-2016-currentstemcellreports-2-171016142602-thumbnail.jpg?width=120&height=120&fit=bounds" /> Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development Carlo Tremolada1 & Valeria Colombo1 & Carlo Ventura2 Abstract Inthepastfewyears,interestinadiposetissueasan ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered Bmini-drugstores.^ MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinicalresults.Moreover, these techniquesare hampered by complex regulatory issues. Therefore, an innovative technique (Lipogems®; Lipogems International SpA, Milan, Italy) was developed to obtain microfragmented adipose tissue with an intact stromal vascular niche and MSCs with a high regenerative capacity. The Lipogems® technology, patented in 2010 and clinically available since 2013, is an easyto-use system designed to harvest, process, and inject refined fat tissue and is characterized by optimal handling ability and a great regenerative potential based on adipose-derived MSCs. In this novel technology, the adipose tissue is washed, emulsified, and rinsed and adipose cluster dimensions gradually are reduced to about 0.3 to 0.8 mm. In the resulting Lipogems® product, pericytes are retained within an intact stromal vascular niche and are ready to interact with the recipient tissue after transplantation, thereby becoming MSCs and starting the regenerative process. Lipogems® has been used in more than 7000 patients worldwide in aesthetic medicineandsurgery,aswellasinorthopedicandgeneralsurgery, with remarkable and promising results and seemingly no drawbacks. Now, several clinical trials are under way to supporttheinitialencouragingoutcomes.Lipogems®technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes.

Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems速 Technology Development from Lipogems Equine & Lipogems Canine

]]> 431 6 https://cdn.slidesharecdn.com/ss_thumbnails/tremoladaetal-2016-currentstemcellreports-2-171016142602-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cell /slideshow/angiogenic-and-antiinflammatory-properties-of-microfragmented-fat-tissue-and-its-derived-mesenchymal-stromal-cell/80860136 vascularcell2016-171016142216
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells Valentina Ceserani1†, Anna Ferri1*†, Angiola Berenzi2, Anna Benetti2, Emilio Ciusani3, Luisa Pascucci4, Cinzia Bazzucchi4, Valentina Coccè5, Arianna Bonomi5, Augusto Pessina5, Erica Ghezzi6, Offer Zeira6, Piero Ceccarelli4, Silvia Versari7, Carlo Tremolada7 and Giulio Alessandri1 Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population.]]>
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells Valentina Ceserani1†, Anna Ferri1*†, Angiola Berenzi2, Anna Benetti2, Emilio Ciusani3, Luisa Pascucci4, Cinzia Bazzucchi4, Valentina Coccè5, Arianna Bonomi5, Augusto Pessina5, Erica Ghezzi6, Offer Zeira6, Piero Ceccarelli4, Silvia Versari7, Carlo Tremolada7 and Giulio Alessandri1 Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population.]]> Mon, 16 Oct 2017 14:22:16 GMT /slideshow/angiogenic-and-antiinflammatory-properties-of-microfragmented-fat-tissue-and-its-derived-mesenchymal-stromal-cell/80860136 lipogemsequine@slideshare.net(lipogemsequine) Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cell lipogemsequine Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells Valentina Ceserani1†, Anna Ferri1*†, Angiola Berenzi2, Anna Benetti2, Emilio Ciusani3, Luisa Pascucci4, Cinzia Bazzucchi4, Valentina Coccè5, Arianna Bonomi5, Augusto Pessina5, Erica Ghezzi6, Offer Zeira6, Piero Ceccarelli4, Silvia Versari7, Carlo Tremolada7 and Giulio Alessandri1 Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/vascularcell2016-171016142216-thumbnail.jpg?width=120&height=120&fit=bounds" /> Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells Valentina Ceserani1†, Anna Ferri1*†, Angiola Berenzi2, Anna Benetti2, Emilio Ciusani3, Luisa Pascucci4, Cinzia Bazzucchi4, Valentina Coccè5, Arianna Bonomi5, Augusto Pessina5, Erica Ghezzi6, Offer Zeira6, Piero Ceccarelli4, Silvia Versari7, Carlo Tremolada7 and Giulio Alessandri1 Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population.

Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cell from Lipogems Equine & Lipogems Canine

]]> 92 4 https://cdn.slidesharecdn.com/ss_thumbnails/vascularcell2016-171016142216-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 IFATS Presentation by Dr offer Zeira - 2016 20.11.16 /slideshow/ifats-presentation-by-dr-offer-zeira-2016-201116/80859604 ifats201620-171016140829
14th Annual IFATS Meeting November 17-20, 2016 San Diego, California: AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE IN DOGS WITH ARTHROPATIES: SAFETY, FEASIBILITY AND CLINICAL OUTCOME. By Offer Zeira, San Michele Veterinary Hospital]]>
14th Annual IFATS Meeting November 17-20, 2016 San Diego, California: AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE IN DOGS WITH ARTHROPATIES: SAFETY, FEASIBILITY AND CLINICAL OUTCOME. By Offer Zeira, San Michele Veterinary Hospital]]> Mon, 16 Oct 2017 14:08:29 GMT /slideshow/ifats-presentation-by-dr-offer-zeira-2016-201116/80859604 lipogemsequine@slideshare.net(lipogemsequine) IFATS Presentation by Dr offer Zeira - 2016 20.11.16 lipogemsequine 14th Annual IFATS Meeting November 17-20, 2016 San Diego, California: AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE IN DOGS WITH ARTHROPATIES: SAFETY, FEASIBILITY AND CLINICAL OUTCOME. By Offer Zeira, San Michele Veterinary Hospital <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ifats201620-171016140829-thumbnail.jpg?width=120&height=120&fit=bounds" /> 14th Annual IFATS Meeting November 17-20, 2016 San Diego, California: AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE IN DOGS WITH ARTHROPATIES: SAFETY, FEASIBILITY AND CLINICAL OUTCOME. By Offer Zeira, San Michele Veterinary Hospital

IFATS Presentation by Dr offer Zeira - 2016 20.11.16 from Lipogems Equine & Lipogems Canine

]]> 128 3 https://cdn.slidesharecdn.com/ss_thumbnails/ifats201620-171016140829-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With Videos /slideshow/lipocast-biotech-uk-lipogems-canine-veterinary-presentation-2017-v13-with-videos-80859163/80859163 lipocastbiotechuklipogemscanineveterinarypresentation2017v-171016135704
This presentation is for qualified registered small animal veterinary surgeons who are interested in using Lipogems Canine. The presentation outlines the science behind the concept, an outline of the procedure, some case study data and links for further reading. Please be aware this presentation contains videos and therefore the file is very large and may take some time to download. For a quick download please request the link for the quick PDF download. ]]>
This presentation is for qualified registered small animal veterinary surgeons who are interested in using Lipogems Canine. The presentation outlines the science behind the concept, an outline of the procedure, some case study data and links for further reading. Please be aware this presentation contains videos and therefore the file is very large and may take some time to download. For a quick download please request the link for the quick PDF download. ]]> Mon, 16 Oct 2017 13:57:04 GMT /slideshow/lipocast-biotech-uk-lipogems-canine-veterinary-presentation-2017-v13-with-videos-80859163/80859163 lipogemsequine@slideshare.net(lipogemsequine) Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With Videos lipogemsequine This presentation is for qualified registered small animal veterinary surgeons who are interested in using Lipogems Canine. The presentation outlines the science behind the concept, an outline of the procedure, some case study data and links for further reading. Please be aware this presentation contains videos and therefore the file is very large and may take some time to download. For a quick download please request the link for the quick PDF download. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemscanineveterinarypresentation2017v-171016135704-thumbnail.jpg?width=120&height=120&fit=bounds" /> This presentation is for qualified registered small animal veterinary surgeons who are interested in using Lipogems Canine. The presentation outlines the science behind the concept, an outline of the procedure, some case study data and links for further reading. Please be aware this presentation contains videos and therefore the file is very large and may take some time to download. For a quick download please request the link for the quick PDF download.

Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With Videos from Lipogems Equine & Lipogems Canine

]]> 105 4 https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemscanineveterinarypresentation2017v-171016135704-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 /slideshow/lipocast-biotech-uk-lipogems-equine-and-canine-presentation-2017-v12/80783251 lipocastbiotechuklipogemsequineandcaninepresentation2017v-171013155217
This presentation is a short preview of the translated technology. It outlines the science behind the concept and explains some of the misconceptions of tissue graft technology. The preview also contains extensive links to online published research papers and retrospective studies.]]>
This presentation is a short preview of the translated technology. It outlines the science behind the concept and explains some of the misconceptions of tissue graft technology. The preview also contains extensive links to online published research papers and retrospective studies.]]> Fri, 13 Oct 2017 15:52:16 GMT /slideshow/lipocast-biotech-uk-lipogems-equine-and-canine-presentation-2017-v12/80783251 lipogemsequine@slideshare.net(lipogemsequine) Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 lipogemsequine This presentation is a short preview of the translated technology. It outlines the science behind the concept and explains some of the misconceptions of tissue graft technology. The preview also contains extensive links to online published research papers and retrospective studies. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineandcaninepresentation2017v-171013155217-thumbnail.jpg?width=120&height=120&fit=bounds" /> This presentation is a short preview of the translated technology. It outlines the science behind the concept and explains some of the misconceptions of tissue graft technology. The preview also contains extensive links to online published research papers and retrospective studies.

Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 from Lipogems Equine & Lipogems Canine

]]> 363 7 https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineandcaninepresentation2017v-171013155217-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With videos /slideshow/lipocast-biotech-uk-lipogems-equine-veterinary-presentation-2017-v14-with-videos/80782743 lipocastbiotechuklipogemsequineveterinarypresentation2017v-171013153820
A presentation of the science behind Lipogems and its application for equine use, this presentation also includes an outline of the procedure and case study data. This presentation is only for the use of qualified registered veterinary surgeons.]]>
A presentation of the science behind Lipogems and its application for equine use, this presentation also includes an outline of the procedure and case study data. This presentation is only for the use of qualified registered veterinary surgeons.]]> Fri, 13 Oct 2017 15:38:20 GMT /slideshow/lipocast-biotech-uk-lipogems-equine-veterinary-presentation-2017-v14-with-videos/80782743 lipogemsequine@slideshare.net(lipogemsequine) Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With videos lipogemsequine A presentation of the science behind Lipogems and its application for equine use, this presentation also includes an outline of the procedure and case study data. This presentation is only for the use of qualified registered veterinary surgeons. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineveterinarypresentation2017v-171013153820-thumbnail.jpg?width=120&height=120&fit=bounds" /> A presentation of the science behind Lipogems and its application for equine use, this presentation also includes an outline of the procedure and case study data. This presentation is only for the use of qualified registered veterinary surgeons.

Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With videos from Lipogems Equine & Lipogems Canine

]]> 235 5 https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineveterinarypresentation2017v-171013153820-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - Without Videos /slideshow/lipocast-biotech-uk-lipogems-equine-veterinary-presentation-2017-v14-without-videos/80778758 lipocastbiotechuklipogemsequineveterinarypresentation2017v-171013135222
An extended preview covering the translated science from huma to equine application with a review of the procedure and case study data. This preview is only intended for qualified registered veterinary surgeons. For quick download - videos have been de-activated in PDF format. For active videos please download the PP Presentation version.]]>
An extended preview covering the translated science from huma to equine application with a review of the procedure and case study data. This preview is only intended for qualified registered veterinary surgeons. For quick download - videos have been de-activated in PDF format. For active videos please download the PP Presentation version.]]> Fri, 13 Oct 2017 13:52:22 GMT /slideshow/lipocast-biotech-uk-lipogems-equine-veterinary-presentation-2017-v14-without-videos/80778758 lipogemsequine@slideshare.net(lipogemsequine) Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - Without Videos lipogemsequine An extended preview covering the translated science from huma to equine application with a review of the procedure and case study data. This preview is only intended for qualified registered veterinary surgeons. For quick download - videos have been de-activated in PDF format. For active videos please download the PP Presentation version. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineveterinarypresentation2017v-171013135222-thumbnail.jpg?width=120&height=120&fit=bounds" /> An extended preview covering the translated science from huma to equine application with a review of the procedure and case study data. This preview is only intended for qualified registered veterinary surgeons. For quick download - videos have been de-activated in PDF format. For active videos please download the PP Presentation version.

Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - Without Videos from Lipogems Equine & Lipogems Canine

]]> 582 9 https://cdn.slidesharecdn.com/ss_thumbnails/lipocastbiotechuklipogemsequineveterinarypresentation2017v-171013135222-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-lipogemsequine-48x48.jpg?cb=1563196822 A New Generation of Regeneration for Your Horse or Dog Lipogems® Equine Lipogems® Canine and is a new innovative application of regenerative medicine, it is unlike any other regenerative therapy available for treating your horse, pony or dog. Unlike many other veterinary treatments Lipogems® has been translated from the human medical sciences to the veterinary world with a background of extraordinary results. www.lipogemsequine.com or www.lipogemscanine.com @lipogemsequine @lipogemscanine #savingchampions #savingyourbestfriend www.lipogemsequine.com https://cdn.slidesharecdn.com/ss_thumbnails/26-27eqlifemay19-lipogemsfinal-190529083402-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/equestrian-life-june-2019/148099917 Equestrian Life June 2... https://cdn.slidesharecdn.com/ss_thumbnails/aselectionoflipogemscaninecasestudiesv1-181016151016-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/a-selection-of-lipogems-canine-case-studies-v1/119613895 A Selection of Lipogem... https://cdn.slidesharecdn.com/ss_thumbnails/intra-1-180724105034-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/intraarticular-administration-of-autologous-microfragmented-adipose-tissue-in-dogs-with-spontaneous-osteoarthritis-safety-feasibility-and-clinical-outcomes/107283235 Intra-Articular Admini...